Top

Published in:

Open Access 01-12-2021 | Endometrial Cancer | Research

Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis

Authors: Soichiro Kakimoto, Morikazu Miyamoto, Takahiro Einama, Yasuhiro Takihata, Hiroko Matsuura, Hideki Iwahashi, Hiroki Ishibashi, Takahiro Sakamoto, Taira Hada, Jin Suminokura, Tsubasa Ito, Rie Suzuki, Ayako Suzuki, Masashi Takano

Published in: Diagnostic Pathology | Issue 1/2021

Abstract

Background

This study aimed to investigate the association between clinicopathologic factors, mesothelin, and cancer antigen (CA) 125 in endometrial carcinoma.

Methods

Between 1989 and 2017, patients with endometrial carcinoma who underwent total hysterectomy and bilateral salpingo-oophorectomy at our hospital were identified. The association between either or both immunochemical expression of mesothelin and CA125 and clinicopathological features were retrospectively examined.

Results

Among 485 patients, 171 were positive for mesothelin, 368 were positive for CA125, and 167 were positive for mesothelin and CA125. The expression of mesothelin and CA125 was positively correlated (p < 0.01). More patients with mesothelin expression showed myometrial invasion of more than 50% (p = 0.028) and positive lymphovascular invasion (p = 0.027). Similarly, more patients with co-expression of mesothelin and CA125 had myometrial invasion of more than 50% (p = 0.016) and positive lymphovascular invasion (p = 0.02). Patients with mesothelin expression and co-expression of mesothelin and CA125 demonstrated worse progression-free survival (PFS) and overall survival (OS). In the multivariate analysis, mesothelin expression and co-expression were poor prognostic factors for PFS (mesothelin expression: hazard ratio [HR] = 2.14, p < 0.01; co-expression: HR = 2.19, p < 0.01) and OS (mesothelin expression: HR = 2.18, p < 0.01; co-expression: HR = 2.22, p < 0.01).

Conclusions

Mesothelin expression and co-expression might be associated with tumor aggressiveness and poor prognosis in patients with endometrial carcinoma. Persons with mesothelin-expressing endometrial cancers present a particularly high medical unmet need.

Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258–79. https://doi.org/10.3322/caac.21561.CrossRefPubMed

Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094–108. https://doi.org/10.1016/S0140-6736(15)00130-0.CrossRefPubMed

Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2, Part 1):383–97. https://doi.org/10.1097/AOG.0b013e3182605bf1.CrossRefPubMed

Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992;50(3):373–81. https://doi.org/10.1002/ijc.2910500308.CrossRefPubMed

Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93(1):136–40. https://doi.org/10.1073/pnas.93.1.136.CrossRefPubMedPubMedCentral

Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50.CrossRef

Li YR, Xian RR, Ziober A, Conejo-Garcia J, Perales-Puchalt A, June CH, et al. Mesothelin expression is associated with poor outcomes in breast cancer. Breast Cancer Res Treat. 2014;147(3):675–84. https://doi.org/10.1007/s10549-014-3077-5.CrossRefPubMedPubMedCentral

Shiraishi T, Shinto E, Mochizuki S, Tsuda H, Kajiwara Y, Okamoto K, et al. Mesothelin expression has prognostic value in stage ΙΙ/ΙΙΙ colorectal cancer. Virchows Arch. 2019;474(3):297–307. https://doi.org/10.1007/s00428-018-02514-4.CrossRefPubMed

Nahm CB, Turchini J, Jamieson N, Moon E, Sioson L, Itchins M, et al. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: a multi-institutional cohort study. Eur J Surg Oncol. 2019;45(2):218–24. https://doi.org/10.1016/j.ejso.2018.10.050.CrossRefPubMed

10.

Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, et al. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas. 2011;40(8):1276–82. https://doi.org/10.1097/MPA.0b013e318221bed8.CrossRefPubMed

11.

Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279(10):9190–8. https://doi.org/10.1074/jbc.M312372200.CrossRefPubMed

12.

Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N, et al. Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. 2012;107(1):137–42. https://doi.org/10.1038/bjc.2012.235.CrossRefPubMedPubMedCentral

13.

Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Ishikawa M, et al. Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms. Oncol Lett. 2015;9(4):1583–9. https://doi.org/10.3892/ol.2015.2969.CrossRefPubMedPubMedCentral

14.

Yildiz Y, Kabadayi G, Yigit S, Kucukzeybek Y, Alacacioglu A, Varol U, et al. High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis. J BUON. 2019;24(4):1549–54.PubMed

15.

Inoue S, Tsunoda T, Riku M, Ito H, Inoko A, Murakami H, et al. Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncol Lett. 2020;19(3):1741–50. https://doi.org/10.3892/ol.2020.11290.CrossRefPubMedPubMedCentral

16.

Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13(1):129. https://doi.org/10.1186/1476-4598-13-129.CrossRefPubMedPubMedCentral

17.

Dainty LA, Risinger JI, Morrison C, Chandramouli GV, Bidus MA, Zahn C, et al. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol. 2007;105(3):563–70. https://doi.org/10.1016/j.ygyno.2006.10.063.CrossRefPubMed

18.

Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M, Avinoach I. Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer. 2002;12(4):372–5. https://doi.org/10.1046/j.1525-1438.2002.01007.x.CrossRefPubMed

19.

Metindir J, Dilek GB, Pak I. Staining characterization by immunohistochemistry of tumor cancer antigen in patients with endometrial cancer. Eur J Gynaecol Oncol. 2008;29(5):489–92.PubMed

20.

Kakimoto S, Miyamoto M, Einama T, Matsuura H, Iwahashi H, Ishibashi H, et al. Co-expression of mesothelin and CA125 is associated with the poor prognosis of endometrial serous carcinoma and mixed carcinomas including serous carcinoma. Pathol Oncol Res. 2020;26(4):2299–306. https://doi.org/10.1007/s12253-020-00823-1.CrossRefPubMed

21.

WHO. Classification of tumors editorial board: female Genital Organs. 5th ed. Lyon: International Agency for Research on Cancer; 2020. p. 245–66.

22.

Chen W, Husain A, Nelson GS, Nelson GS, Rambau PF, Liu S, et al. Immunohistochemical profiling of endometrial serous carcinoma. Int J Gynecol Pathol. 2017;36(2):128–39. https://doi.org/10.1097/PGP.0000000000000291.CrossRefPubMed

23.

Li W, Li L, Wu M, Lang J, Bi Y. The prognosis of stage ia mixed endometrial carcinoma. Am J Clin Pathol. 2019;152(5):616–24. https://doi.org/10.1093/ajcp/aqz083.CrossRefPubMed

24.

DeLair DF, Burke KA, Selenica P, Lim RS, Scott SN, Middha S, et al. The genetic landscape of endometrial clear cell carcinomas. J Pathol. 2017;243(2):230–41. https://doi.org/10.1002/path.4947.CrossRefPubMedPubMedCentral

25.

Cantrell LA, Blank SV, Duska LR. Uterine carcinosarcoma: a review of the literature. Gynecol Oncol. 2015;137(3):581–8. https://doi.org/10.1016/j.ygyno.2015.03.041.CrossRefPubMed

26.

Singh N, Hirschowitz L, Zaino R, Alvarado-Cabrero I, Duggan MA, Ali-Fehmi R, et al. Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade). Int J Gynecol Pathol. 2019;38:S93–S113. https://doi.org/10.1097/PGP.0000000000000524.CrossRefPubMed

27.

Ørtoft G, Lausten-Thomsen L, Høgdall C, Hansen ES, Dueholm M. Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish gynecological Cancer group study. J Gynecol Oncol. 2019;30(5):e84. https://doi.org/10.3802/jgo.2019.30.e84.CrossRefPubMedPubMedCentral

28.

van der Putten LJ, van de Vijver K, Bartosch C, Davidson B, Gatius S, Matias-Guiu X, et al. Reproducibility of measurement of myometrial invasion in endometrial carcinoma. Virchows Arch. 2017;470(1):63–8. https://doi.org/10.1007/s00428-016-2035-5.CrossRefPubMed

29.

He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, et al. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer. 2017;16(1):63. https://doi.org/10.1186/s12943-017-0633-8.CrossRefPubMedPubMedCentral

30.

Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol Cancer. 2011;10(1):106. https://doi.org/10.1186/1476-4598-10-106.CrossRefPubMedPubMedCentral

31.

Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M, et al. Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol. 2012;105(2):195–9. https://doi.org/10.1002/jso.22024.CrossRefPubMed

32.

Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res. 2006;12(3):827–31. https://doi.org/10.1158/1078-0432.CCR-05-1397.CrossRefPubMed

33.

Vizcaya D, Farahmand B, Walter AO, Kneip C, Jöhrens K, Tukiainen M, et al. Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland. Cancer Treat Res Commun. 2020;25:100260. https://doi.org/10.1016/j.ctarc.2020.100260.CrossRefPubMed

34.

Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol. 2016;34(34):4171–9. https://doi.org/10.1200/JCO.2016.68.3672.CrossRefPubMedPubMedCentral

35.

Lv J, Li P. Mesothelin as a biomarker for targeted therapy. Biomark Res. 2019;7(1):18. https://doi.org/10.1186/s40364-019-0169-8.CrossRefPubMedPubMedCentral

36.

Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, et al. Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther. 2016;15(3):439–47. https://doi.org/10.1158/1535-7163.MCT-15-0693.CrossRefPubMed

37.

Lazzerini L, Jöhrens K, Sehouli J, Cichon G. Favorable therapeutic response after anti-mesothelin antibody-drug conjugate treatment requires high expression of mesothelin in tumor cells. Arch Gynecol Obstet. 2020;302(5):1255–62. https://doi.org/10.1007/s00404-020-05734-9.CrossRefPubMedPubMedCentral

Title: Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis
Authors: Soichiro Kakimoto
Morikazu Miyamoto
Takahiro Einama
Yasuhiro Takihata
Hiroko Matsuura
Hideki Iwahashi
Hiroki Ishibashi
Takahiro Sakamoto
Taira Hada
Jin Suminokura
Tsubasa Ito
Rie Suzuki
Ayako Suzuki
Masashi Takano
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Endometrial Cancer
Endometrial Cancer
Published in: Diagnostic Pathology / Issue 1/2021
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-021-01093-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Clinicopathological significance of primitive phenotypes in early gastric cancer with differentiated histology

Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples

CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squamous cell carcinoma

Atypical cells parameter in Sysmex UN automated urine analyzer: feedback from the field

LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2

Morphological predictors for microsatellite instability in urothelial carcinoma